JP2016503793A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503793A5 JP2016503793A5 JP2015549643A JP2015549643A JP2016503793A5 JP 2016503793 A5 JP2016503793 A5 JP 2016503793A5 JP 2015549643 A JP2015549643 A JP 2015549643A JP 2015549643 A JP2015549643 A JP 2015549643A JP 2016503793 A5 JP2016503793 A5 JP 2016503793A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- optionally substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261738822P | 2012-12-18 | 2012-12-18 | |
| US61/738,822 | 2012-12-18 | ||
| PCT/US2013/076214 WO2014100228A1 (en) | 2012-12-18 | 2013-12-18 | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019109822A Division JP6852118B2 (ja) | 2012-12-18 | 2019-06-12 | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503793A JP2016503793A (ja) | 2016-02-08 |
| JP2016503793A5 true JP2016503793A5 (enExample) | 2017-02-02 |
| JP6542127B2 JP6542127B2 (ja) | 2019-07-10 |
Family
ID=50979162
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549643A Active JP6542127B2 (ja) | 2012-12-18 | 2013-12-18 | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2019109822A Active JP6852118B2 (ja) | 2012-12-18 | 2019-06-12 | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2021038515A Active JP7241792B2 (ja) | 2012-12-18 | 2021-03-10 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2023034402A Active JP7589275B2 (ja) | 2012-12-18 | 2023-03-07 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2024197865A Pending JP2025024078A (ja) | 2012-12-18 | 2024-11-13 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019109822A Active JP6852118B2 (ja) | 2012-12-18 | 2019-06-12 | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2021038515A Active JP7241792B2 (ja) | 2012-12-18 | 2021-03-10 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2023034402A Active JP7589275B2 (ja) | 2012-12-18 | 2023-03-07 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| JP2024197865A Pending JP2025024078A (ja) | 2012-12-18 | 2024-11-13 | 向神経活性１９－アルコキシ－１７－置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (8) | US9676812B2 (enExample) |
| EP (3) | EP2935307B1 (enExample) |
| JP (5) | JP6542127B2 (enExample) |
| KR (3) | KR102265408B1 (enExample) |
| CN (3) | CN105026415B (enExample) |
| AU (5) | AU2013361485B2 (enExample) |
| BR (1) | BR112015014397B1 (enExample) |
| CA (1) | CA2895513C (enExample) |
| CY (1) | CY1121150T1 (enExample) |
| DK (1) | DK2935307T3 (enExample) |
| ES (2) | ES2933987T3 (enExample) |
| HR (1) | HRP20181048T1 (enExample) |
| HU (1) | HUE039057T2 (enExample) |
| IL (3) | IL310501A (enExample) |
| LT (1) | LT2935307T (enExample) |
| MX (2) | MX388946B (enExample) |
| NZ (2) | NZ739760A (enExample) |
| PH (2) | PH12018502141A1 (enExample) |
| PL (1) | PL2935307T3 (enExample) |
| PT (2) | PT3392260T (enExample) |
| RS (1) | RS57390B1 (enExample) |
| RU (1) | RU2663665C2 (enExample) |
| SG (3) | SG10201809638YA (enExample) |
| SI (2) | SI2935307T1 (enExample) |
| SM (1) | SMT201800422T1 (enExample) |
| TR (1) | TR201808616T4 (enExample) |
| WO (1) | WO2014100228A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| US20150158903A1 (en) | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| WO2013112605A2 (en) | 2012-01-23 | 2013-08-01 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| BR112015014397B1 (pt) | 2012-12-18 | 2021-02-02 | Washington University | composto, composição farmacêutica e uso de um composto |
| LT2968369T (lt) | 2013-03-13 | 2018-12-27 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai ir jų panaudojimo būdai |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| HRP20200995T1 (hr) | 2013-04-17 | 2020-11-27 | Sage Therapeutics, Inc. | 19-nor neuroaktivni steroidi za metode liječenja |
| HRP20190232T1 (hr) | 2013-04-17 | 2019-03-22 | Sage Therapeutics, Inc. | 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| SMT202100229T1 (it) * | 2013-07-19 | 2021-05-07 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| SMT202100048T1 (it) | 2013-08-23 | 2021-03-15 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| AU2015331749A1 (en) | 2014-10-16 | 2017-05-04 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| JP6742308B2 (ja) | 2014-10-16 | 2020-08-19 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
| ES2793237T3 (es) | 2014-11-27 | 2020-11-13 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| SI3250210T1 (sl) * | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AR105044A1 (es) | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| MX376833B (es) | 2015-07-06 | 2025-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| RS62220B1 (sr) | 2015-07-06 | 2021-09-30 | Sage Therapeutics Inc | Oksisteroli i postupci njihovog korišćenja |
| EP3362042A1 (en) | 2015-10-16 | 2018-08-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| US20200306262A1 (en) * | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| SG11201807785VA (en) | 2016-03-08 | 2018-10-30 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| CN114272249A (zh) | 2016-04-01 | 2022-04-05 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2017292870B2 (en) | 2016-07-07 | 2021-10-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN109689673B (zh) | 2016-07-11 | 2023-03-14 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| WO2018031748A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| EP3519422B1 (en) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| ES2952106T3 (es) | 2016-10-18 | 2023-10-27 | Sage Therapeutics Inc | Oxisteroles y procedimientos de utilización de los mismos |
| KR20250054838A (ko) | 2016-10-18 | 2025-04-23 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| CN109988210B (zh) * | 2017-12-30 | 2022-05-17 | 天津药业研究院股份有限公司 | 一种黄体酮和黄体酮中间体的制备方法 |
| EP3864022B1 (en) | 2018-10-12 | 2023-09-20 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| CN109289095B (zh) * | 2018-11-23 | 2021-03-26 | 淮海工学院 | 一种含盐酸利多卡因的肠镜凝胶剂及其制备方法 |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| CA3145923A1 (en) | 2019-08-05 | 2021-02-11 | David Czekai | Ganaxolone for use in treatment of status epilepticus |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| WO2021113834A1 (en) | 2019-12-06 | 2021-06-10 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| US20230346801A1 (en) | 2020-03-25 | 2023-11-02 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| CN117801047B (zh) * | 2023-01-19 | 2024-12-20 | 北京华睿鼎信科技有限公司 | 神经甾体衍生物及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB820780A (en) * | 1954-12-08 | 1959-09-23 | Syntex Sa | Cyclopentanophenanthrene derivatives |
| US2856415A (en) * | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| BE632431A (enExample) * | 1962-05-16 | |||
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US4239681A (en) * | 1974-04-15 | 1980-12-16 | Richardson-Merrell Inc. | Androst-4-en-19-ols |
| US4022769A (en) * | 1974-05-13 | 1977-05-10 | Richardson-Merrell Inc. | Androst-4-en-19-ones |
| US4139617A (en) * | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
| US4071625A (en) * | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| MA18433A1 (fr) * | 1978-05-26 | 1979-12-31 | Ciba Geigy Ag | Procede pour la synthese de la chaine laterale hydroxyacetyle de steroides du type pregnagne, nouveaux 21-hydroxy-20-oxo-17 alpha-pregnagnes et produits pharmaceutiques en renfermant |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) * | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| US5661141A (en) * | 1995-03-27 | 1997-08-26 | Petrow; Vladimir | 19-oxygenated steroids as therapeutic agents |
| KR19990022323A (ko) * | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| WO2002036605A2 (en) * | 2000-11-03 | 2002-05-10 | Washington University | Estrone-derivatives having cytoprotective activity |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| EA011123B1 (ru) | 2003-03-24 | 2008-12-30 | Стерикс Лимитед | Производные эстрогена в качестве ингибиторов стероидной сульфатазы |
| CN1281561C (zh) * | 2003-04-23 | 2006-10-25 | 中国科学院上海有机化学研究所 | 一种具有1，6－亚甲基－[10]－轮烯基本骨架的化合物及其用途 |
| US7781421B2 (en) * | 2003-05-29 | 2010-08-24 | Washington University | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods |
| JP2007512344A (ja) * | 2003-11-24 | 2007-05-17 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体調節剤 |
| CN100376685C (zh) * | 2005-01-14 | 2008-03-26 | 天津科技大学 | 微生物转化法制备雌酚酮的方法 |
| CA2604887A1 (en) * | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| AU2008265898B2 (en) * | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| EP2598513A1 (en) * | 2010-07-30 | 2013-06-05 | Medexis S.A. | Compounds and methods for treating neoplasia |
| EP2667876A2 (en) | 2010-12-15 | 2013-12-04 | Harbor BioSciences, Inc. | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP2695948B1 (en) | 2011-03-23 | 2016-12-28 | Etsuro Ito | Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate |
| US20150175651A1 (en) * | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2014058736A1 (en) * | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| BR112015014397B1 (pt) | 2012-12-18 | 2021-02-02 | Washington University | composto, composição farmacêutica e uso de um composto |
| US9562026B2 (en) * | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| SMT202100048T1 (it) * | 2013-08-23 | 2021-03-15 | Sage Therapeutics Inc | Steroidi neuroattivi, composizioni e loro usi |
-
2013
- 2013-12-18 BR BR112015014397-0A patent/BR112015014397B1/pt active IP Right Grant
- 2013-12-18 HU HUE13865411A patent/HUE039057T2/hu unknown
- 2013-12-18 RS RS20180807A patent/RS57390B1/sr unknown
- 2013-12-18 DK DK13865411.6T patent/DK2935307T3/en active
- 2013-12-18 CN CN201380072706.2A patent/CN105026415B/zh active Active
- 2013-12-18 US US14/652,717 patent/US9676812B2/en active Active
- 2013-12-18 EP EP13865411.6A patent/EP2935307B1/en active Active
- 2013-12-18 ES ES18162373T patent/ES2933987T3/es active Active
- 2013-12-18 JP JP2015549643A patent/JP6542127B2/ja active Active
- 2013-12-18 PL PL13865411T patent/PL2935307T3/pl unknown
- 2013-12-18 AU AU2013361485A patent/AU2013361485B2/en active Active
- 2013-12-18 MX MX2019006739A patent/MX388946B/es unknown
- 2013-12-18 TR TR2018/08616T patent/TR201808616T4/tr unknown
- 2013-12-18 WO PCT/US2013/076214 patent/WO2014100228A1/en not_active Ceased
- 2013-12-18 SG SG10201809638YA patent/SG10201809638YA/en unknown
- 2013-12-18 LT LTEP13865411.6T patent/LT2935307T/lt unknown
- 2013-12-18 NZ NZ739760A patent/NZ739760A/en unknown
- 2013-12-18 MX MX2015007900A patent/MX365644B/es active IP Right Grant
- 2013-12-18 EP EP18162373.7A patent/EP3392260B1/en active Active
- 2013-12-18 CA CA2895513A patent/CA2895513C/en active Active
- 2013-12-18 ES ES13865411.6T patent/ES2680582T3/es active Active
- 2013-12-18 KR KR1020197018089A patent/KR102265408B1/ko active Active
- 2013-12-18 IL IL310501A patent/IL310501A/en unknown
- 2013-12-18 NZ NZ709211A patent/NZ709211A/en unknown
- 2013-12-18 PT PT181623737T patent/PT3392260T/pt unknown
- 2013-12-18 PH PH12018502141A patent/PH12018502141A1/en unknown
- 2013-12-18 SI SI201331092T patent/SI2935307T1/en unknown
- 2013-12-18 PT PT138654116T patent/PT2935307T/pt unknown
- 2013-12-18 IL IL278396A patent/IL278396B2/en unknown
- 2013-12-18 KR KR1020217017732A patent/KR102400891B1/ko active Active
- 2013-12-18 EP EP22166199.4A patent/EP4086270B1/en active Active
- 2013-12-18 SG SG10201706063UA patent/SG10201706063UA/en unknown
- 2013-12-18 CN CN201811630997.3A patent/CN109970833B/zh active Active
- 2013-12-18 SG SG11201504848QA patent/SG11201504848QA/en unknown
- 2013-12-18 HR HRP20181048TT patent/HRP20181048T1/hr unknown
- 2013-12-18 CN CN202210026684.7A patent/CN114605486A/zh active Pending
- 2013-12-18 SM SM20180422T patent/SMT201800422T1/it unknown
- 2013-12-18 SI SI201332021T patent/SI3392260T1/sl unknown
- 2013-12-18 RU RU2015129546A patent/RU2663665C2/ru active
- 2013-12-18 US US14/132,386 patent/US9630986B2/en active Active
- 2013-12-18 KR KR1020157019442A patent/KR101993899B1/ko active Active
-
2015
- 2015-06-18 PH PH12015501404A patent/PH12015501404B1/en unknown
- 2015-06-18 IL IL239501A patent/IL239501B/en active IP Right Grant
-
2017
- 2017-03-15 US US15/459,492 patent/US10342809B2/en active Active
- 2017-05-04 US US15/586,853 patent/US20170232006A1/en not_active Abandoned
-
2018
- 2018-07-03 CY CY20181100686T patent/CY1121150T1/el unknown
- 2018-08-14 AU AU2018217213A patent/AU2018217213B2/en active Active
-
2019
- 2019-05-22 US US16/419,255 patent/US20200113916A1/en not_active Abandoned
- 2019-06-12 JP JP2019109822A patent/JP6852118B2/ja active Active
-
2020
- 2020-03-20 AU AU2020202016A patent/AU2020202016C1/en active Active
-
2021
- 2021-03-10 JP JP2021038515A patent/JP7241792B2/ja active Active
- 2021-06-21 US US17/304,433 patent/US20210308149A1/en not_active Abandoned
- 2021-12-20 AU AU2021290223A patent/AU2021290223B2/en active Active
-
2023
- 2023-02-09 US US18/107,965 patent/US20230190770A1/en not_active Abandoned
- 2023-03-07 JP JP2023034402A patent/JP7589275B2/ja active Active
-
2024
- 2024-04-08 AU AU2024202233A patent/AU2024202233A1/en not_active Abandoned
- 2024-11-13 JP JP2024197865A patent/JP2025024078A/ja active Pending
-
2025
- 2025-10-09 US US19/354,165 patent/US20260034146A1/en active Pending